Methyl acetylsalicylic acid, also known as aspirin, is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties. It is synthesized through the acetylation of salicylic acid with acetic anhydride. Aspirin works by inhibiting the production of prostaglandins, which are chemicals that cause pain, fever, and inflammation. It is widely used for the treatment of headaches, fever, pain, and inflammation, and has been shown to reduce the risk of heart attacks and strokes. Aspirin's effects on the cardiovascular system, its potential for gastrointestinal side effects, and its role in various diseases make it a subject of ongoing research.'
methyl acetylsalicylic acid: has less gastrointestinal side effects than aspirin; structure in Merck Index, 9th ed, #5886 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 68484 |
| CHEMBL ID | 163148 |
| SCHEMBL ID | 1162463 |
| MeSH ID | M0092696 |
| Synonym |
|---|
| benzoic acid, 2-(acetyloxy)-, methyl ester |
| methyl rhodin |
| methyl aspirin |
| nsc-403847 |
| methyl acetylsalicylate |
| methyl o-acetylsalicylate |
| methylrhodine |
| methyl o-acetoxybenzoate |
| aspirin methyl ester |
| nsc403847 |
| 580-02-9 |
| salicylic acid acetate, methyl ester |
| inchi=1/c10h10o4/c1-7(11)14-9-6-4-3-5-8(9)10(12)13-2/h3-6h,1-2h |
| A0114 |
| methyl 2-acetoxybenzoate |
| 2-acetoxybenzoic acid methyl ester |
| acetylsalicylic acid methyl ester |
| methyl 2-acetyloxybenzoate |
| 2-acetoxy-benzoic acid methyl ester |
| CHEMBL163148 |
| 7fx481v180 , |
| nsc 403847 |
| unii-7fx481v180 |
| ai3-02356 |
| einecs 209-450-4 |
| methyl acetylsalicylic acid |
| AKOS006227738 |
| FT-0628767 |
| methyl acetylsalicylate [mi] |
| SCHEMBL1162463 |
| acetylsalicylsauremethylester |
| ONWPLBKWMAUFGZ-UHFFFAOYSA-N |
| salicylic acid, methyl ester, acetate |
| o-acetyl methyl salicylate |
| methyl 2-(acetyloxy)benzoate # |
| DTXSID20206724 |
| mfcd00014978 |
| methyl 2-(acetyloxy)benzoate |
| AS-58237 |
| methylacetylsalicylate |
| CS-0272202 |
| E78191 |
| Q27268210 |
| HY-W209628 |
| EN300-7465515 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID21167 | Percent unaltered compound in human serum after 1 hr of incubation | 2003 | Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5 | Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. |
| AID23285 | Partition coefficient (logP) | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID15845 | Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID17241 | Observed second order rate constant | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID21168 | Percent unaltered compound in human serum after 1 min of incubation | 2003 | Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5 | Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. |
| AID1398207 | Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay | 2018 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17 | Novel cinnamaldehyde-based aspirin derivatives for the treatment of colorectal cancer. |
| AID18526 | Observed pseudo-first order rate constant | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID160927 | Inhibition of collagen-induced human platelet rich plasma aggregation | 2003 | Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5 | Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. |
| AID25694 | t1/2 in 10% human plasma | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| AID20532 | Solubility (21 degrees C) | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.44) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||